PURPOSE: The aim of the International Myeloma Working Group was to develop practice recommendations for the management of multiple myeloma (MM) -related bone disease. METHODOLOGY: An interdisciplinary panel of clinical experts on MM and myeloma bone disease developed recommendations based on published data through August 2012. Expert consensus was used to propose additional recommendations in situations where there were insufficient published data. Levels of evidence and grades of recommendations were assigned and approved by panel members. RECOMMENDATIONS: Bisphosphonates (BPs) should be considered in all patients with MM receiving first-line antimyeloma therapy, regardless of presence of osteolytic bone lesions on conventional radiography. However, it is unknown if BPs offer any advantage in patients with no bone disease assessed by magnetic resonance imaging or positron emission tomography/computed tomography. Intravenous (IV) zoledronic acid (ZOL) or pamidronate (PAM) is recommended for preventing skeletal-related events in patients with MM. ZOL is preferred over oral clodronate in newly diagnosed patients with MM because of its potential antimyeloma effects and survival benefits. BPs should be administered every 3 to 4 weeks IV during initial therapy. ZOL or PAM should be continued in patients with active disease and should be resumed after disease relapse, if discontinued in patients achieving complete or very good partial response. BPs are well tolerated, but preventive strategies must be instituted to avoid renal toxicity or osteonecrosis of the jaw. Kyphoplasty should be considered for symptomatic vertebral compression fractures. Low-dose radiation therapy can be used for palliation of uncontrolled pain, impending pathologic fracture, or spinal cord compression. Orthopedic consultation should be sought for long-bone fractures, spinal cord compression, and vertebral column instability.
PURPOSE: The aim of the International Myeloma Working Group was to develop practice recommendations for the management of multiple myeloma (MM) -related bone disease. METHODOLOGY: An interdisciplinary panel of clinical experts on MM and myeloma bone disease developed recommendations based on published data through August 2012. Expert consensus was used to propose additional recommendations in situations where there were insufficient published data. Levels of evidence and grades of recommendations were assigned and approved by panel members. RECOMMENDATIONS: Bisphosphonates (BPs) should be considered in all patients with MM receiving first-line antimyeloma therapy, regardless of presence of osteolytic bone lesions on conventional radiography. However, it is unknown if BPs offer any advantage in patients with no bone disease assessed by magnetic resonance imaging or positron emission tomography/computed tomography. Intravenous (IV) zoledronic acid (ZOL) or pamidronate (PAM) is recommended for preventing skeletal-related events in patients with MM. ZOL is preferred over oral clodronate in newly diagnosed patients with MM because of its potential antimyeloma effects and survival benefits. BPs should be administered every 3 to 4 weeks IV during initial therapy. ZOL or PAM should be continued in patients with active disease and should be resumed after disease relapse, if discontinued in patients achieving complete or very good partial response. BPs are well tolerated, but preventive strategies must be instituted to avoid renal toxicity or osteonecrosis of the jaw. Kyphoplasty should be considered for symptomatic vertebral compression fractures. Low-dose radiation therapy can be used for palliation of uncontrolled pain, impending pathologic fracture, or spinal cord compression. Orthopedic consultation should be sought for long-bone fractures, spinal cord compression, and vertebral column instability.
Authors: Gareth J Morgan; Faith E Davies; Walter M Gregory; Alex J Szubert; Sue E Bell; Mark T Drayson; Roger G Owen; A John Ashcroft; Graham H Jackson; J Anthony Child Journal: Blood Date: 2012-04-12 Impact factor: 22.113
Authors: James R Berenson; Ori Yellin; Ralph V Boccia; Marshall Flam; Siu-Fun Wong; Olcay Batuman; Mehdi M Moezi; Donald Woytowitz; Herbert Duvivier; Youram Nassir; Regina A Swift Journal: Clin Cancer Res Date: 2008-10-01 Impact factor: 12.531
Authors: C I Ripamonti; M Maniezzo; T Campa; E Fagnoni; C Brunelli; G Saibene; C Bareggi; L Ascani; E Cislaghi Journal: Ann Oncol Date: 2008-07-22 Impact factor: 32.976
Authors: Gareth J Morgan; J Anthony Child; Walter M Gregory; Alex J Szubert; Kim Cocks; Sue E Bell; Nuria Navarro-Coy; Mark T Drayson; Roger G Owen; Sylvia Feyler; A John Ashcroft; Fiona M Ross; Jennifer Byrne; Huw Roddie; Claudius Rudin; Gordon Cook; Graham H Jackson; Ping Wu; Faith E Davies Journal: Lancet Oncol Date: 2011-07-21 Impact factor: 41.316
Authors: Karthik Nath; Vibooshini Ganeshalingam; Barbara Ewart; Elizabeth Heyer; Kerrianne Watt; Andrew Birchley; John Casey; Hock Choong Lai; Edward Morris; Georgina Hodges Journal: Support Care Cancer Date: 2019-06-21 Impact factor: 3.603
Authors: Ramón García-Sanz; Albert Oriol; María J Moreno; Javier de la Rubia; Angel R Payer; Miguel T Hernández; Luis Palomera; Ana I Teruel; María J Blanchard; Mercedes Gironella; Paz Ribas; Joan Bargay; Eugenia Abellá; Miquel Granell; Enrique M Ocio; Josep M Ribera; Jesús F San Miguel; María V Mateos Journal: Haematologica Date: 2015-06-11 Impact factor: 9.941
Authors: Jo Caers; Carlos Fernández de Larrea; Xavier Leleu; Roy Heusschen; Niklas Zojer; Olivier Decaux; Efstathios Kastritis; Monique Minnema; Artur Jurczyszyn; Yves Beguin; Ralph Wäsch; Antonio Palumbo; Meletios Dimopoulos; Maria Victoria Mateos; Heinz Ludwig; Monika Engelhardt Journal: Oncologist Date: 2016-02-26
Authors: E Terpos; D Christoulas; E Kastritis; M Roussou; M Migkou; E Eleutherakis-Papaiakovou; M Gavriatopoulou; M Gkotzamanidou; N Kanellias; E Manios; C Papadimitriou; M A Dimopoulos Journal: Leukemia Date: 2013-09-18 Impact factor: 11.528